Saururus cernuus lignans -: Potent small molecule inhibitors of hypoxia-inducible factor-1

被引:69
作者
Hossain, CF
Kim, YP
Baerson, SR
Zhang, L
Bruick, RK
Mohammed, KA
Agarwal, AK
Nagle, DG [1 ]
Zhou, YD
机构
[1] Univ Mississippi, Sch Pharm, Dept Pharmacognosy, Pharmaceut Sci Res Inst, University, MS 38677 USA
[2] USDA ARS, Natl Prod Utilizat Res Unit, University, MS 38677 USA
[3] Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA
[4] Univ Mississippi, Sch Pharm, Natl Ctr Nat Prod Res, Pharmaceut Sci Res Inst, University, MS 38677 USA
关键词
hypoxia; breast cancer; HIF-1; inhibitor; natural product; small molecule; dineolignan; sesquineolignan; manassantin; Saururus cernuus;
D O I
10.1016/j.bbrc.2005.05.191
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hypoxia-inducible factor-1 (HIF-1) represents an important tumor-selective therapeutic target for solid tumors. In search of novel small molecule HIF-1 inhibitors, 5400 natural product-rich extracts from plants, marine organisms, and microbes were examined for HIF-1 inhibitory activities using a cell-based reporter assay. Bioassay-guided fractionation and isolation, followed by structure elucidation, yielded three potent natural product-derived HIF-1 inhibitors and two structurally related inactive compounds. In a T47D cell-based reporter assay, manassantin B-1, manassantin A, and 4-O-methylsaucerneol inhibited hypoxia-induced HIF-1 activation with IC50 values of 3, 3, and 20 nM, respectively. All three compounds are relatively hypoxia-specific inhibitors of HIF-1 activation, in comparison to other stimuli. The hypoxic induction of HIF-1 tar.-et genes CDKN1A, VEGF, and GLUT-1 were also inhibited. These compounds inhibit HIF-1 by blocking hypoxia-induced nuclear HIF-1 alpha protein accumulation without affecting HIF-1 alpha mRNA levels. In addition, preliminary structure-activity Studies suggest specific structural requirements for this class of HIF-1 inhibitors. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:1026 / 1033
页数:8
相关论文
共 43 条
[1]  
[Anonymous], 1982, PHYTOCHEMISTRY, DOI DOI 10.1016/S0031-9422(00)82432-2
[2]   Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma [J].
Bos, R ;
van der Groep, P ;
Greijer, AE ;
Shvarts, A ;
Meijer, S ;
Pinedo, HM ;
Semenza, GL ;
van Diest, PJ ;
van der Wall, E .
CANCER, 2003, 97 (06) :1573-1581
[3]   Levels of hypoxia-inducible factor-1α during breast carcinogenesis [J].
Bos, R ;
Zhong, H ;
Hanrahan, CF ;
Mommers, ECM ;
Semenza, GL ;
Pinedo, HM ;
Abeloff, MD ;
Simons, JW ;
van Diest, PJ ;
van der Wall, E .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (04) :309-314
[4]   Exploiting tumour hypoxia in cancer treatment [J].
Brown, JM ;
William, WR .
NATURE REVIEWS CANCER, 2004, 4 (06) :437-447
[5]   Mitochondrial reactive oxygen species trigger hypoxia-induced transcription [J].
Chandel, NS ;
Maltepe, E ;
Goldwasser, E ;
Mathieu, CE ;
Simon, MC ;
Schumacker, PT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (20) :11715-11720
[6]   The biology of VEGF and its receptors [J].
Ferrara, N ;
Gerber, HP ;
LeCouter, J .
NATURE MEDICINE, 2003, 9 (06) :669-676
[7]   HIF-1 as a target for drug development [J].
Giaccia, A ;
Siim, BG ;
Johnson, RS .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (10) :803-811
[8]   Redistribution of intracellular oxygen in hypoxia by nitric oxide:: Effect on HIF1α [J].
Hagen, T ;
Taylor, CT ;
Lam, F ;
Moncada, S .
SCIENCE, 2003, 302 (5652) :1975-1978
[9]  
HARTWELL JL, 1971, LLOYD, V34, P204
[10]  
HATTORI M, 1987, CHEM PHARM BULL, V35, P3315